PrintFriendly

Print Friendly, PDF & Email

New Medscape Activity Makes the Case for Gene Therapy

September 12, 2018
New Medscape Activity Makes the Case for Gene Therapy

Medscape has launched a new educational activity in their “Clinical Advances in Gene Therapy for Hemophilia” series, which is presented through a collaboration between Medscape, the National Hemophilia Foundation, the European Haemophilia Consortium and the World Federation of Hemophilia. The program is supported by an independent educational grant from BioMarin.

“Why Gene Therapy for Hemophilia? Exploring the Challenges of Current Therapies,” is a discussion about the current clinical challenges associated with the use of factor replacement therapy in hemophilia patients and the part gene therapy may play in the future. Upon completion of this activity, participants will have increased knowledge regarding the potential role of gene therapy to address challenges in current hemophilia treatment.

Why Gene Therapy for Hemophilia? Exploring the Challenges of Current Therapies
Authors: John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPCH; Johnny Mahlangu, BSc, MBBCh, MMed, FCPath
CME/ ABIM MOC Released: 8/23/2018
Valid for credit through: 8/30/2019

If you are already registered with Medscape follow this link to “Why Gene Therapy for Hemophilia? Exploring the Challenges of Current Therapies.”

Access this link to visit the “Clinical Advances in Gene Therapy for Hemophilia” homepage.

If you are not already registered, go to Medscape.org where registration is straightforward and free of charge.